<DOC>
	<DOCNO>NCT00689780</DOCNO>
	<brief_summary>A Phase I , Multi-Centre , Randomised , Double-blind , Placebo-controlled Study Investigate Safety , Tolerability Pharmacokinetics AZD1940 , Including Interaction Study , After Administration Oral Multiple Ascending Doses Adult Subjects Chronic Low Back Pain</brief_summary>
	<brief_title>Study Investigate Safety , Tolerability Pharmacokinetics AZD1940</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>A diagnosis Chronic Low Back Pain accord Quebec Task force Class 13 average pain intensity score 39 NRS ( 010 ) past week . Clinical normal physical finding , include blood pressure , pulse rate &gt; 45bpm , ECG ( normal QTcF interval &lt; 450msec without additional risk factor Torsades de Pointes ) laboratory assessment , judge investigator Body Mass Index ( BMI ) ≥18 ≤32 kg/m2 inclusive body weight ≥50 ≤100 kg History somatic disease/condition may interfere objective study , exception Chronic Low Back Pain History previous ongoing psychiatric disease/condition include psychosis , affective disorder , anxiety disorder , borderline state personality disorder Clinically significant illness exception Chronic Low Back Pain</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Pain</keyword>
	<keyword>safety</keyword>
	<keyword>chronic low back pain</keyword>
</DOC>